Huntington's disease: pathogenesis to animal models
- PMID: 20360611
- DOI: 10.1016/s1734-1140(10)70238-3
Huntington's disease: pathogenesis to animal models
Abstract
Huntington's disease (HD) is an inherited genetic disorder, characterized by cognitive dysfunction and abnormal body movements called chorea. George Huntington, an Ohio physician, described the disease precisely in 1872. HD is a dominantly inherited disorder, characterized by progressive neurodegeneration of the striatum but also involves other regions, primarily the cerebral cortex. The mutation responsible for this fatal disease is an abnormally expanded and unstable CAG repeat within the coding region of the gene encoding the huntingtin protein. Various hypotheses have been put forward to explain the pathogenic mechanisms of mutant huntingtin-induced neuronal dysfunction and cell death. None of these hypotheses, however, offers a clear explanation; thus, it remains a topic of research interest. HD is considered to be an important disease, embodying many of the major themes in modern neuroscience, including molecular genetics, selective neuronal vulnerability, excitotoxicity, mitochondrial dysfunction, apoptosis and transcriptional dysregulation. A number of recent reports have concluded that oxidative stress plays a key role in HD pathogenesis. Although there is no specific treatment available to block disease progression, treatments are available to help in controlling the chorea symptoms. As animal models are the best tools to evaluate any therapeutic agent, there are also different animal models available, mimicking a few or a larger number of symptoms. Each model has its own advantages and limitations. The present review deals with the pathophysiology and various cascades contributing to HD pathogenesis and progression as well as drug targets, such as dopaminergic, gamma-amino butyric acid (GABA)ergic, glutamate adenosine receptor, peptidergic pathways, cannabinoid receptor, and adjuvant therapeutic drug targets such as oxidative stress and mitochondrial dysfunction that can be targeted for future experimental study. The present review also focuses on the animal models (behavioral and genetic) used to unravel pathogenetic mechanisms and the identification of novel drug targets.
Similar articles
-
Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.J Neurochem. 2001 Aug;78(4):694-703. doi: 10.1046/j.1471-4159.2001.00482.x. J Neurochem. 2001. PMID: 11520890
-
Dopamine and glutamate in Huntington's disease: A balancing act.CNS Neurosci Ther. 2010 Jun;16(3):163-78. doi: 10.1111/j.1755-5949.2010.00134.x. Epub 2010 Apr 8. CNS Neurosci Ther. 2010. PMID: 20406248 Free PMC article. Review.
-
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.Curr Neuropharmacol. 2019;17(2):165-175. doi: 10.2174/1570159X16666180302115032. Curr Neuropharmacol. 2019. PMID: 29512464 Free PMC article. Review.
-
Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.J Huntingtons Dis. 2013;2(2):217-28. doi: 10.3233/JHD-130057. J Huntingtons Dis. 2013. PMID: 25063516
-
Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.Adv Neurobiol. 2017;15:93-128. doi: 10.1007/978-3-319-57193-5_4. Adv Neurobiol. 2017. PMID: 28674979 Review.
Cited by
-
Mild cognitive impairment in Huntington's disease: challenges and outlooks.J Neural Transm (Vienna). 2024 Apr;131(4):289-304. doi: 10.1007/s00702-024-02744-8. Epub 2024 Jan 24. J Neural Transm (Vienna). 2024. PMID: 38265518 Review.
-
Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.J Intern Med. 2010 Nov;268(5):419-31. doi: 10.1111/j.1365-2796.2010.02275.x. J Intern Med. 2010. PMID: 20964734 Free PMC article. Review.
-
Beta-Boswellic Acid Reverses 3-Nitropropionic Acid-Induced Molecular, Mitochondrial, and Histopathological Defects in Experimental Rat Model of Huntington's Disease.Biomedicines. 2022 Nov 9;10(11):2866. doi: 10.3390/biomedicines10112866. Biomedicines. 2022. PMID: 36359390 Free PMC article.
-
Sodium selenite protects from 3-nitropropionic acid-induced oxidative stress in cultured primary cortical neurons.Mol Biol Rep. 2019 Feb;46(1):751-762. doi: 10.1007/s11033-018-4531-y. Epub 2018 Dec 3. Mol Biol Rep. 2019. PMID: 30511305
-
Mechanisms of altered redox regulation in neurodegenerative diseases--focus on S--glutathionylation.Antioxid Redox Signal. 2012 Mar 15;16(6):543-66. doi: 10.1089/ars.2011.4119. Epub 2012 Jan 6. Antioxid Redox Signal. 2012. PMID: 22066468 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials